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ABSTRACT
Aims: The prognostic value of different clinical, echocardiographic and functional
parameters was evaluated in clinically stable outpatients with heart failure due to
idiopathic dilated cardiomyopathy (DCM).
Study Design: Observational prospective study.
Methodology: 56 patients suffering from idiopathic dilated cardiomyopathy in waiting
list for heart transplantation (33 men and 23 women, mean age 56.4 years) and in
clinical stable conditions for a minimum of 3 months underwent baseline clinical
evaluation, echocardiogram, 6 minute walk test (6 MWT) and  cardiopulmonary exercise
test (CPET). They were followed for an average period of 26.5 months to assess event-
free survival (death, heart transplantation).
Results: During follow-up period 23 patients died, 21 for cardiovascular causes. 4
patients underwent heart transplantation. Age and sex were not related to survival. We
found a significant predictive value for 6MWTD (at 1 year event-free survival was 53%
for a distance <300 m), but not for VO2 peak or respectively anaerobic threshold (AT).
At multivariate analysis using Cox-stepwise regression model NYHA class, 6MWTD, left
ventricular ejection fraction and left ventricular end diastolic diameter were independent
prognostic markers of survival.
Conclusion: An advanced NYHA class, a higher LVEDD and a distance of < 300m at
6MWT are useful prognostic markers of event free survival in outpatients with stable
DCM while CPET was not.
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1. INTRODUCTION
Several studies have supported the value of cardiopulmonary exercise test (CPET) in
functional evaluation of patients with heart failure and peak oxygen consumption (VO2 peak)
has been reported as the most sensitive independent prognostic index of survival (Cohn and
Rector, 1988; Pilote et al., 1989). Heart transplantation is indicated when VO2 peak falls
under 10-12 ml/kg/min (Szlachcic et al., 1985; Mancini et al., 1991). Six minutes walk test
(6MWT) has been proposed as a simple, safe and inexpensive alternative to
cardiopulmonary exercise test (Guyatt et al., 1985). The prognostic usefulness of 6MWT was
first reported by Bittner et al. (1993) in patients included in the Studies of Left Ventricular
Dysfunction (SOLVD) Trial  and subsequently confirmed by other authors both in patients
with moderate (NYHA II-III class) or severe heart failure of different etiologies (mainly
coronary artery disease)  undergoing evaluation for heart transplantation (Lipkin et al., 1986;
Lucas et al., 1999; Rostagno et al., 2003 ), although  accuracy of 6MWT to predict mortality
in advanced heart failure was not confirmed by other authors (Aaronson, 1999).
However most of the studies evaluating the usefulness of the different methods of
cardiovascular functional evaluation were performed before  widespread introduction of beta-
blockers, ACE-inhibitors (or AT1 inhibitors) or aldosterone inhibitors, thus that rarely a
population of clinically stable outpatients with heart failure in waiting list for heart transplant
may be examined.
Aim of present study was to prospectively evaluate the role of 6-minute walk test as
prognostic factor both for mortality and overall event free survival (death plus heart
transplant) in patients with clinically stable heart failure (CHF) due to idiopathic dilated
cardiomyopathy (DCM) and to compare it to other  indexes  of cardiovascular  function, in
particular to VO2 peak.
2. MATERIALS AND METHODS
In the study were included 56 consecutive patients with clinically stable diopathic dilated
cardiomyopathy consecutively referred to our institution for clinical and functional evaluation
from 01.01.04 to 06.30.04. Thirty-three patients were males and 23 females. Age ranged
from 29 to 68 years (mean age 56.3 years). Clinical characteristics of patients are reported
in Table 1.
Ten patients were in NYHA class I, 26 in class II and 20 in class III-IV. Diagnosis of primary
dilated cardiomyopathy was made according to the criteria proposed by the working group of
the European Society of Cardiology and absence of significant coronary disease (stenosis
>50% of one of the main coronary artery) had been confirmed by coronary angiography.
None of these patients has history of alcohol abuse or uncontrolled arterial hypertension.
Patients were in treatment with diuretics (73%), ACE-inhibitors or AT1 –inhibitors (88%),
beta-blockers (92%). The dosage of diuretics was not changed in the 48 hours preceding
functional evaluation.
British Journal of Medicine & Medical Research, 2(3): 386-395, 2012
388
2.1 Study Design
The severity of symptoms was assessed using the New York Heart Association functional
classification (AHA Medical/Scientific Statement, 1994). Within 3 days from hospital
admission all the patients underwent chest X-ray and echocardiographic evaluation.
Cardiopulmonary stress testing and 6-minute-walk corridor test were performed during two
subsequent days at the same hour in the morning in a randomly assigned sequence.
Table 1. Clinical characteristics of patients according to NYHA classes
LVEDD = left ventricular end diastolic diameter, LVEF= left ventricular ejection fraction, PAP= systolic
pulmonary artery pressure, pVO2=peak oxygen consumption, AT= anaerobic threshold
2.2 Cardiopulmonary Exercise Test
Cardiopulmonary exercise test was conducted at treadmill according to previously described
methods (Stevenson, 1996; Rostagno et al., 2003). Cardiopulmonary functional capacity was
assessed by determining the anaerobic threshold (AT) and the peak of oxygen consumption
by expired gas analysis (OXYCON ALFA -JAEGER, Wuertzburg, Germany). According to
VO2 peak patients were subdivided into three groups (group I >20 ml/kg/min, group II
between 15 and 20 ml/kg /min and group III between 10 and 15 ml/kg /min).
2.3 6 Minute Walk Corridor Test
The walk test was performed, as previously reported (Rostagno et al., 2003), in an indoor
corridor 25 m long according to the suggestions of Guyatt et al. (1985). At the end of the six
minutes the physician measured the distance walked by the patient. On the basis of the
distance walked, performance was grouped into 3 different levels (level I >450 m, level II
300-450 m, level III < 300 m). The repeatability of the test was assessed in 50 patients by
performing the test twice in the same day.
2.4 Other Measurements
Echocardiographic examination was performed in the left side recumbent position using a
SIM 5000 echocardiograph (Esaote Biomedica, Florence Italy) with monoplane probes (2.50
and 3.75 Mhz). Measurements were made according to the recommendations of the
American Society of Echocardiography (Henry et al., 1980). Patients were subdivided in 3
groups according to LVEF: group I > 40%, group II 30-40% group III < 30%.
Clinical characteristics Class I (10) Class II (26) Class III-IV(20) ANOVA
Age (years) 57.9+ 9.8 65.4+10.0 65.2 +10.4 <0.0001
Follow-up (months) 39.6+15.1 37.8+16.2 26.3+16.4 <0.0001
6MWD (m) 427+71 367+90 242+100 <0.0001
LVEDD (mm) 54.7+9.7 60.0+11.4 63.2+8.9 0.0002
LVEF % 52.5+12.8 42.7+15.1 33.1+14.2 <0.0001
E/A ratio 0.93+0.37 1.27++0.8 1.55+1.16 0.05
PAP (mmHg) 22.7+8.3 29.0+9.0 32.2++10.2 <0.0001
pVO2 (ml/kg/min) 21.6+5.3 18.2+3.7 17.4+4.0 0.012
AT (ml/kg/min) 18.7+3.9 15.5+2.8 14.9+3.1 0.0036
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Systolic pulmonary pressure was calculated adding right ventricle/right atrium pressure
gradient to estimated right atrium pressure.
The study has been approved by ethical committee of AOU-Careggi. Informed consent was
given by all patients.
2.5 Statistical Analysis
Results were expressed as the mean ± standard deviation. Differences among groups were
evaluated using the Student’s t test. Correlation among different variables was evaluated
with the standard regression coefficient analysis. Univariate analysis was performed by chi-
square test with Yates’ correction when necessary. Survival was analysed by the Kaplan
Meier method and survival curves were compared by the log-rank test. Cox proportional
hazards model was used for multivariate survival analysis. A value of p<0.05 was
considered statistically significant.
3. RESULTS AND DISCUSSION
Patients were followed as outpatients with periodical control every 6 months. During an
average follow-up period of   26.5 + 17 months 23 patients died (41%), 21 of cardiovascular
causes (17 refractory heart failure, 4 sudden death), 1 for lung cancer and 1 for the
consequences of stroke. 4 patients underwent heart transplantation.
3.1 6 Minute Walk Test
Patients who walked less than 300 m had a significantly higher risk of death or need for
urgent heart transplant in comparison to groups who had an intermediate (300-450 m) or
respectively an high level of performance  (>450 m). Although the difference among groups
was already significant at 12 months, at 36 months event free survival was 53% in patients
with 6MWD < 300 m, in comparison to 72% and respectively 92% in the other two groups.
Survival curve in  patients who walked less than 300 m  was significantly worse than those
obtained in the other two groups – log rank test 2 =6.26 , p=0.044 (Fig. 1).
Fig. 1. Kaplan-Meier curves for 6 minute walk test according to the distance walked
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3.2 Cardiopulmonary Exercise Test
A VO2 peak above 20 ml/kg/min was associated with a good prognosis (event-free survival
87% at 36 months). Actuarial survival curves did not show any significant difference in event-
free survival in patients with VO2 peak comprised between 15 and 20 ml/kg/min and
respectively VO2 peak comprised 10 and 15 ml/kg /min, At 36 month’s event free- survival
were respectively 35 % and 42% (Fig. 2).


















Fig. 2. Kaplan – Meier curves for peak oxygen consumption
To limit age and weight related variability of VO2 peak measurement, percent of predicted
oxygen consumption reached during cardiopulmonary test was calculated for each patient.
No significant differences were found among groups stratified according to percent of
predicted oxygen consumption.
3.3 Other Variables
We did not find any significant difference in prognosis when patients were stratified
according to age: event free survival at 36 months was 20% for the younger group (< 55
years) and 28% in the other two groups (56-65 years, >65 years).
Survival was 91% in patients in NYHA I class, 83% in patients in NYHA II class, a difference
not statistically significant. In patients in advanced NYHA classes (III-IV) survival was less
than 50%. In these last patients Kaplan Meier survival curve was statistically different
(p<0.0001 in comparison to both other groups). Both left ventricular end diastolic diameter
and left ventricular ejection fraction were associated with event free survival.
A restrictive pattern of left ventricular filling (characterized by an E/A ratio >2) was
associated with a significantly higher event-free survival was significantly lower in
comparison to patients with normal pattern of left ventricular filling (64 vs 85%).
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Pulmonary hypertension (mean pulmonary artery pressure > 30 mmHg) was related to a
significantly lower 3 year survival (62% in comparison to 76% of patients with normal or
slightly elevated pulmonary artery pressure).
3.4 Comparison with Other Variables
The relation with event free survival of various clinical, echocardiographic and functional
parameters, categorized into different groups as described in method section, was
examined. An advanced NYHA class (III-IV) was related to a significant lower probability of
event free survival. A significant statistical relation with survival was found also for low LV
ejection fraction, higher LV end-diastolic diameter and a restrictive pattern of LV diastolic
filling (Table 2).
Table 2. Univariate analysis
2 P
Age- years 2.13 0.34
LVEF (%) 23.21 0.0001
LVFS(%) 18.78 0.0005
LVEDD mm 15.75 0.001
NYHA class 41.6 0.0001
AT (ml/kg/min) 0.023 0.877
pVO2 (ml/kg/min) 0.024 0.877
6 MWD –meters 9.68 0.007
MPAP-mmHg 5.919 0.0518
E/A ratio 17.19 0.0002
LVFS= fractional shortening, LVEF= left ventricular ejection fraction, LVEDD = left ventricular end
diastolic diameter, AT= anaerobic threshold, pVO2=peak oxygen consumption, MPAP= mean
pulmonary artery pressure.
Among functional indexes only a distance covered during 6MWT < 300 m was statistically
related to a decreased event free survival while we failed to find any statistically significant
relation between mortality and VO2 peak or anaerobic threshold subgroups. The correction
for age and weight using percent of predicted VO2 peak values did not improve the predictive
value of CPET.  At multivariate analysis using Cox stepwise regression model, LV fractional
shortening and the distance covered during 6MW were the strongest prognostic indexes,
although LVEF, LVEDD and systolic pulmonary artery pressure were significantly related to
event free survival (Table 3). The risk of death increased by 2.58 times for each change in
NYHA class and decreased by 5/1000 per every meter walked at 6MWT.
3.5 Discussion
The prognostic value of VO2 peak at CPET in patients with advanced heart failure has been
fully established (Mancini et al., 1991) and a value <10 ml/min/kg is universally accepted as
indication for heart transplant. However these results have been obtained in highly selected
groups and before the widespread introduction of beta-blockers and ACE-inhibitors (or AT1
inhibitors). At present few investigations have been performed to evaluate the prognostic
value of different clinical and laboratory parameters in patients with full medical treatment
and stable heart failure. Present investigation has been performed in ambulatory patients in
waiting list for heart transplant with established diagnosis of idiopathic dilated
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cardiomyopathy who has been clinically stable for at least 3 months before investigation.
Three year event free survival (death or heart transplant) has been 55%.
Table 3. Multivariate analysis
Hazard ratio (CI 95%) P
Age-years 1.007   (0.98-1.03) 0.58
NYHA class 2.58     (1.87-3.57) 0.000
AT(ml/kg/min) 0.99     (0.85-1.15) 0.85
pVO2(ml/kg/min) 1.01     (0.91-1.11) 0.84
6 MWD m 0.995   (0.993-0.997) 0.000
MPAP mmHg 1.03     (1.00-1.06) 0.028
E/A ratio 1.23     (0.90-1.69) 0.181
LVFS= fractional shortening, LVEF= left ventricular ejection fraction, LVEDD = left ventricular end
diastolic diameter, AT= anaerobic threshold, pVO2=peak oxygen consumption, MPAP= mean
pulmonary artery pressure,
Our results indicate that the distance covered during 6 minute walk test is an independent
predictor of survival in this selected group of patients.  In particular mortality is significantly
higher in the group of patients who covered less than 300 m during the test. The prognostic
significance of low LV ejection fraction, high (III-IV) NYHA class, pulmonary hypertension
and a restrictive pattern of left ventricular filling are in agreement with previous investigations
in patients with heart failure due to different etiologies (Ho et al., 1993; Xie et al., 1994;
Pinamonti, 1997; Myers et al., 1998). At variance we were not able to identify any significant
predictive value of pVO2 in the group of patients under investigation. Survival curves did not
significantly differ between patients who reached or did not reach a VO2 peak of 14
ml/kg/min. As reported in the methods section all patients reached anaerobic threshold.
The demonstration that a cheap and simple method of functional evaluation such as 6MWD
is provided with an independent prognostic value in patients with clinically stable DCM is of
high practical relevance allowing patients to be followed also in peripheral centers. Although
even NYHA classification has a relevant discriminator power however is not very clinically
useful because it allows an almost binary distribution (event free survival 80-90 in class
NYHA I-II, 50% or less in NYHA class III-IV).
Prognostic value of 6MWD in patients with heart failure was first reported by Bittner et al.
(1993). They followed 898 patients with left ventricular dysfunction or radiological evidence
of pulmonary congestion from the SOLVD investigation for a mean period of 242 days.
Mortality was 10.23% in patients who walked less than 350 m in comparison to 2.99%
(p<0.01) in patients who walked more than 450 m.  Ejection fraction and the distance walked
resulted as independent predictors of mortality or hospitalization.
Roul et al. (1998) followed 121 patients with mild to moderate heart failure (II-III NYHA
Class) due to systolic dysfunction (average LVEF 29+13%) for a mean period of 18 months.
Distance walked during 6MWT was not significantly lower in patients who reached the
combined end point of death or hospitalization for heart failure in comparison to event-free
group (410+26m vs 448+92m) while VO2 peak  was significantly higher in event free patients
(18.5 + 4  ml/kg/min vs 13.9+4 ml/kg/min, p<0.0001). However patients who walked less
than 300m had a higher rate of combined events of death and hospitalization.
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The prognostic value of 6MWT has been studied also in patients with severe heart failure
(III-IV NYHA classes) referred for heart transplantation. Swedberg et al. (1995) evaluated
359 patients in a multicentric trial of continuous epoprostenol administration. Patients
walking a distance below the median, 210m had a 6 month mortality of 50% vs 20% in
patients who covered a longer distance. Cahalin et al. (1996) studied 45 patients referred for
heart transplantation evaluation. A distance during 6MWT < 300 m predicted an increased
likelihood of death or hospitalization for inotropic or mechanical support within 6 months but
failed to predict overall or event-free survival at a follow-up of 62 weeks. Two studies
performed in stable outpatients with heart failure due to dilated or ischemic cardiomyopathy
(NYHA class II-III) outlined that a distance covered at 6 minute walk test < 300 m was
associated with a significant worse prognosis with a 2 year mortality 4 to 6 folds higher that
in patients with a 6 minute walk test distance > 300m (Urtis et al., 2004; Arlsan, 2007).
The results from present investigation suggest that in a population of clinically stable
outpatients with heart failure due to idiopathic cardiomyopathy a distance walked during six
minute walk test < 300m identify a high risk subgroup with a 3 year event free survival
approaching 60%. In this subset of patients pVO2 at cardiopulmonary exercise test did not
show any predictive value of event-free survival.
4. CONCLUSION
In our opinion 6MWD, in addition to echocardiography, but not CPET may be useful in
clinically stable patients with idiopathic cardiomyopathy to identify subjects at risk of death or
urgent heart transplant due to sudden clinical worsening. It must be underlined that the main
limit of the investigation is the low number of patients included, that does not allow drawing
definite conclusions.
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